We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Register as a manufacturer, importer or distributor of active substances for use in veterinary medicines.
ARSAC advises the licensing authorities on applications from practitioners, employers and researchers who want to use radioactive substances on people. ARSAC works with the Department of Health and Social Care .
Notices of publication and a consolidated list of references of pre-Exit European Assessment Documents for construction products.
International trade mark registrations protected in the EU under the Madrid Protocol will no longer enjoy protection in the UK after 1 January 2021.
Application forms from the Administration of Radioactive Substances Advisory Committee (ARSAC) for employer and practitioner licences under the IR(ME)R.
A summary of recent letters and notifications sent to healthcare professionals about medicines and medical devices.
If you’re a limited company director and provide services to an ‘end client’ then you will encounter IR35 rules.
The MHRA has approved the combined antibiotic cefepime/enmetazobactam (Exblifep 2 g/0.5 g powder for concentrate for solution for infusion)
Batch recall alert for human eye gels that may be prescribed by vets and used under the cascade.
Find out if you can claim Enhanced R&D intensive support (ERIS) as a loss-making, small and medium enterprise (SME) based in Northern Ireland.
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Find out about the registered dealers in controlled oil (RDCO) scheme.
Product defect recall alert for Anesketin 100 mg/ml 5ml Solution for Injection for Dogs, Cats and Horses due to a discrepancy in processing settings.
Specific batches of carbomer gel are being recalled as a precaution due to possible microbiological contamination.
MHRA tells patients and healthcare professionals to stop using affected gels and retailers told to withdraw affected products.
The MHRA has authorised cabotegravir as 30 mg tablets and as a 600 mg long-acting injection administered every two months
medac GmbH (t/a medac Pharma LLP) is recalling the products and respective batches in this notification due to pink discolouration of the dacarbazine solution immediately after reconstitution (after correct preparation and storage).
Novartis Pharmaceuticals UK Limited is recalling Adakveo 10 mg/ml concentrate for solution for infusion due to the benefit-risk balance of Adakveo no longer being considered favourable by the MHRA.
The Interoperable Demand Side Response (IDSR) programme aims to support the development and demonstration of energy smart appliances for the delivery of interoperable demand side response.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).